Related Experiment Video

Updated: Aug 30, 2025

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke
11:32

Evaluating Cell Death Signaling by Immunofluorescence in a Rat Model of Ischemic Stroke

Published on: January 3, 2025

1.1K

Bioinformatics analysis to identify potential biomarkers and therapeutic targets for ST-segment-elevation myocardial

Shuo Feng1, Rui Li1, Qingqing Zhou1

  • 1Stroke Center and Department of Neurology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Frontiers in Neurology
|August 29, 2022
PubMed

Insights

ST-segment-elevation myocardial infarction (STEMI) and ischemic stroke (IS) share common genes. Researchers identified specific genes like MMP9 and ARG1 as potential biomarkers for STEMI-associated IS, offering new therapeutic targets.

Area of Science:

  • Cardiovascular Research
  • Genomics and Bioinformatics
  • Neurology

Background:

  • Acute myocardial infarction (AMI) and ischemic stroke (IS) are leading causes of global mortality and disability.
  • ST-segment-elevation myocardial infarction (STEMI) significantly increases the risk of developing IS.
  • The precise relationship and shared molecular mechanisms between STEMI and IS remain unclear.

Purpose of the Study:

  • To investigate commonly expressed genes in patients with STEMI and IS using bioinformatics.
  • To explore the interrelationship between STEMI and IS disease mechanisms.
  • To identify potential biomarkers and therapeutic targets for STEMI-associated IS.

Main Methods:

  • Differential gene expression analysis of GEO datasets (GSE60993 for STEMI, GSE16561 for IS).
  • Construction and analysis of protein-protein interaction networks for identified DEGs.
  • Gene Ontology (GO) and pathway enrichment analyses.
  • Prediction of microRNAs (miRNAs) targeting co-expressed genes.

Main Results:

  • Identified 210 DEGs in STEMI and 29 DEGs in IS.
  • Key genes associated with STEMI included CD8A, TLR2, TLR4, S100A12, and TREM1.
  • Hub genes for IS implicated IL7R, CCR7, FCGR3B, CD79A, and ITK.
  • Co-expressed DEGs (MMP9, ARG1, CA4, CRISPLD2, S100A12, GZMK) and their targeting by miR-654-5p were linked to STEMI-related IS.

Conclusions:

  • STEMI and IS share underlying molecular connections.
  • Genes such as MMP9, ARG1, CA4, CRISPLD2, S100A12, and GZMK are potential biomarkers for STEMI-associated IS.
  • These identified genes and miRNA interactions may represent novel therapeutic targets.
Abstract

Keywords:
ST-segment-elevation myocardial infarctionbiomarkergene analysisischemic stroketherapeutic targets

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.2K
A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis18:11

A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis

Published on: December 28, 2012

24.3K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
290
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
60
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
195
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
21